EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel enhancers of guanylyl cyclase‐A activity acting via allosteric modulation

Henriette Andresen iD, Cristina Pérez-Ternero iD, Jerid Robinson, Deborah M Dickey, Adrian J Hobbs iD, Lincoln R Potter iD, Finn Olav Levy iD, Alessandro Cataliotti iD, Lise Román Moltzau iD

British Journal of Pharmacology · 2023

DOI: 10.1111/bph.16203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2023. Verfasst von Henriette Andresen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Atrial Natriuretic Factor, Guanylate Cyclase. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, British Heart Foundation, Anders Jahres Fond til Vitenskapens Fremme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Guanylyl cyclase‐A (GC‐A), activated by endogenous atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), plays an important role in the regulation of cardiovascular and renal homeostasis and is an attractive drug target. Even though small molecule modulators allow oral administration and longer half‐life, drug targeting of GC‐A has so far been limited to peptides. Thus, in this study we aimed to develop small molecular activators of GC‐A. Experimental Approach Hits were identified through high‐throughput screening and optimized by in silico design. Cyclic GMP was measured in QBIHEK293A cells expressing GC‐A, GC‐B or chimerae of the two receptors using AlphaScreen technology. Binding assays were performed in membrane preparations or whole cells using 125 I‐ANP. Vasorelaxation was measured in aortic rings isolated from Wistar rats. Key Results We have identified small molecular allosteric enhancers of GC‐A, which enhanced ANP or BNP effects in cellular systems and ANP‐induced vasorelaxation in rat aortic rings. The mechanism of action appears novel and not mediated through previously described allosteric binding sites. In addition, the selectivity and activity depend on a single amino acid residue that differs between the two similar receptors GC‐A and GC‐B. Conclusion and Implications We describe a novel allosteric binding site on GC‐A, which can be targeted by small molecules to enhance ANP and BNP effects. These compounds will be valuable tools in further development and proof‐of‐concept of GC‐A enhancement for the potential use in cardiovascular therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial Natriuretic FactorGuanylate CyclaseRatsAnimalsRats, WistarReceptors, Atrial Natriuretic FactorNatriuretic Peptide, BrainCyclic GMP

Stichwörter der Autor:innen

allosteric modulationcardiovascular pharmacologydrug discovery/target validationguanylyl cyclasenatriuretic peptides

Substanzen

atrial natriuretic factor receptor AAtrial Natriuretic FactorGuanylate CyclaseReceptors, Atrial Natriuretic FactorNatriuretic Peptide, BrainCyclic GMP

Autor:innen und Institutionen

  • Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway.
  • Institute for Experimental Medical Research, University of Oslo and Oslo University Hospital, Oslo, Norway.
  • William Harvey Research Institute, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota Medical School, Minneapolis, Minnesota, USA.

ORCID-Profile: Henriette Andresen, Cristina Pérez-Ternero, Adrian J Hobbs, Lincoln R Potter, Finn Olav Levy, Alessandro Cataliotti, Lise Román Moltzau

Förderung

  • Wellcome Trust
  • British Heart Foundation
  • Anders Jahres Fond til Vitenskapens Fremme
  • Helse Sør-Øst RHF
  • Nasjonalforeningen for Folkehelsen
  • Norges Forskningsråd
  • Universitetet i Oslo

Zitieren

APA

Andresen, H., Pérez-Ternero, C., Robinson, J., Dickey, D. M., Hobbs, A. J., Potter, L. R., Levy, F. O., Cataliotti, A., & Moltzau, L. R. (2023). Novel enhancers of guanylyl cyclase‐A activity acting via allosteric modulation. British Journal of Pharmacology. https://doi.org/10.1111/bph.16203

Vancouver

Andresen H, Pérez-Ternero C, Robinson J, Dickey DM, Hobbs AJ, Potter LR, et al. Novel enhancers of guanylyl cyclase‐A activity acting via allosteric modulation. British Journal of Pharmacology. 2023. doi:10.1111/bph.16203

BibTeX
@article{Andresen2023,
  author = {Andresen, Henriette and Pérez-Ternero, Cristina and Robinson, Jerid and Dickey, Deborah M and Hobbs, Adrian J and Potter, Lincoln R and Levy, Finn Olav and Cataliotti, Alessandro and Moltzau, Lise Román},
  title = {Novel enhancers of guanylyl cyclase‐A activity acting via allosteric modulation},
  journal = {British Journal of Pharmacology},
  year = {2023},
  doi = {10.1111/bph.16203}
}
Kostenlos starten →